Jiangsu Hengrui Medicine Co., Ltd
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- -
- Established
- 1970-01-01
- Employees
- -
- Market Cap
- $38.9B
A Trial of SHR-A1811versus Pyrotinib in Combination With Capecitabine in HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Phase 3
Recruiting
- Conditions
- HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
- Interventions
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2022-08-10
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 269
- Registration Number
- NCT05424835
- Locations
- 🇨🇳
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Study on the Pharmacokinetic Effect of Itraconazole on SHR0302 Tablets in Healthy Subjects
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: itraconazole、 SHR0302 tablets
- First Posted Date
- 2022-06-03
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT05404724
- Locations
- 🇨🇳
The Third Hospital of Changsha, Changsha, Hunan, China
A Trial of SHR0410 Injection in Postsurgical Pain Management
Phase 2
- Conditions
- Postsurgical Pain
- Interventions
- Drug: SHR0410 InjectionDrug: Placebo for SHR0410 Injection
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2022-08-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05394402
- Locations
- 🇨🇳
Union Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China
A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers
Phase 1
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2022-05-26
- Last Posted Date
- 2022-12-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT05392127
- Locations
- 🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
A Study of SHR8554 Injection for the Treatment of Pain After Orthopedic Surgery
Phase 2
Completed
- Conditions
- Pain
- Interventions
- First Posted Date
- 2022-05-16
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 320
- Registration Number
- NCT05375305
- Locations
- 🇨🇳
Shanghai Jiaotong University School of Medicine,Renji Hospital, Shanghai, Shanghai, China
Study of Bioavailability, Pharmacodynamics and Safety of SHR-1209 Administered by Single Subcutaneous Injection at Different Sites in Healthy Volunteers
- First Posted Date
- 2022-05-12
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 159
- Registration Number
- NCT05370950
- Locations
- 🇨🇳
The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
Phase 2
Active, not recruiting
- Conditions
- Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation
- Interventions
- Drug: Camrelizumab、Rivoceranib
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 251
- Registration Number
- NCT05367687
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Phase I Study of HRS-3738 in Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
Phase 1
Recruiting
- Conditions
- Recurrent and Refractory Non-Hodgkin's Lymphoma and Multiple Myeloma
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2022-07-29
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 198
- Registration Number
- NCT05363800
- Locations
- 🇨🇳
Zhejiang University School of Medicine The First Affiliated Hospital, Hangzhou, Zhejiang, China
🇨🇳Henan cancer Hospital, Zhengzhou, Henan, China
🇨🇳Sheng Jing Hospital of China Medical University, Shengyang, Liaoning, China
A Phase Ib/II Study of SHR-A1811 Injection in Breast Cancer
Phase 2
Recruiting
- Conditions
- Breast Cancer
- Interventions
- Drug: SHR-A1811：PyrotinibDrug: SHR-A1811；PertuzumabDrug: SHR-A1811；Adebrelimab
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 402
- Registration Number
- NCT05353361
- Locations
- 🇨🇳
Jiangsu Provincial People's Hospital, Nanjing, Jiangsu, China
A Trial of HR091506 Tablets in Treatment of Primary Gout With Hyperuricemia in Adults
Phase 1
- Conditions
- Primary Gout With Hyperuricemia in Adults
- Interventions
- Drug: HR091506 tablets + placebo of febuxostat tablets
- First Posted Date
- 2022-04-26
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT05347498
© Copyright 2025. All Rights Reserved by MedPath